A Phase 2/3 interventional study of Plasma Rich in Growth Factors (PRGF) and saline in MCL Tear, sponsored by Meir Medical Center. Withdrawn at 1 site in Israel. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2011-07-12.
Sponsored by Meir Medical Center · Phase 2/3, Interventional, and Treatment
To evaluate the influence of Plasma Rich in Growth Factors (PRGF) on the healing process of medial collateral ligament (MCL) tear.
Autologous platelet-rich matrices may aid in the healing of ligaments \& tendons by promoting and accelerating tissue healing because of the release of growth factors including transforming growth factor (TGF)-beta1 and platelet-derived growth factor (PDGF) from platelet alpha-granules.
Meir Medical Center is the lead sponsor of 389 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
saline
Drug: saline
Plasma Rich in Growth Factors (PRGF)
Biological: Plasma Rich in Growth Factors (PRGF)
injection onto injured area in ligament dose: 3-6mg
Also known as: platelet-derived preparation rich in growth factors
injection of 6 cc of saline into injured area
Also known as: saline 0.9% NaCl
time and efficiency of healing
Time frame: 1 year
This study is withdrawn, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Meir Medical Center